

Market Announcement

2 April 2024

SomnoMed Limited (ASX: SOM) – Suspension from Quotation

Description

The securities of SomnoMed Limited ('SOM') will be suspended from quotation immediately under Listing Rule 17.2, at the request of SOM, pending the release of an announcement regarding trading update and earning guidance.

Issued by

ASX Compliance

2 April 2024

Zufishan Anjum
Advisor Listings Compliance
ASX Limited
20 Bridge Street,
Sydney
NSW 2000

Email: tradinghaltssydney@asx.com.au

Dear Zufishan,

SomnoMed Limited ACN 003 255 221 (ASX:SOM) – Request for voluntary suspension

Pursuant to Listing Rule 17.2, SomnoMed Limited (**Company**) requests an immediate voluntary suspension of the securities of SomnoMed Limited.

The Company provides the following information for the purposes of ASX Listing Rule 17.2:

- On 27 March 2024 SomnoMed Limited requested a trading halt, pending the Company making an announcement regarding a trading update and earnings guidance. SomnoMed now requests that trading in its securities be suspended whilst the trading update and guidance are being finalised and whilst it explores future funding options for the Company.
- SomnoMed expects the voluntary suspension to remain in place until the earlier of SomnoMed releasing an announcement regarding the trading update and earnings guidance, or until the commencement of trading on Friday, 5 April 2024.
- SomnoMed is not aware of any reason why the request for voluntary suspension should not be granted, or of any other information necessary to inform the market about the voluntary suspension.

Please contact me if there are any queries regarding this request.

Yours sincerely

Terry Flitcroft
Company Secretary

SomnoMed Limited